All In Biotech

Drug Trial Radar · NCT05799469

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

A Single-arm Exploratory Clinical Study of Envafolimab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

May 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Chongqing University Cancer HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, single-center, exploratory study, the purpose of this study is to evaluate the efficacy and safety of envafolimab combined with Chemoradiotherapy in participants with locally advanced cervical cancer.

Conditions

  • Locally Advanced Cervical Cancer

Interventions

  • EnvafolimabDrug

    SC

  • CisplatinDrug

    IV infusion

  • External Beam Radiotherapy (EBRT)Radiation

    45-50.4Gy

  • Brachytherapy (BT)Radiation

    Performed according to clinically required dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 as Assessed by the InvestigatorTime frame: The cut-off date is event-driven and estimated to be approximately 48 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing university Cancer Hospital

    Chongqing, CHN, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.